Dave A Ricks (@DaveARicks) header
Dave A Ricks (@DaveARicks) profile picture

Chair & CEO @EliLillyandCo. Building on 150 years of advancing human health by delivering breakthrough medicines and expanding access worldwide.

Indianapolis, Indiana
Joined November 2022
Photo by Dave A Ricks (@DaveARicks)
Dave A Ricks retweeted
General Medicine has two announcements with @EliLillyandCo today: GLP-1 weight management on LillyDirect, and a memory care pathway for early Alzheimer’s evaluation. Both show what our store can do for a partner, in very different ways. Weight management is relatively straightforward. But follow-through depends on customers seeing all their options, knowing the price, and having a clinician who understands their whole health picture and goals. We do that. Memory care is complicated. Figuring out what testing someone has had, what they still need, and how it all fits together is hard. As a result, patients often wait years between their first symptoms and a diagnosis. That delay is particularly consequential for new therapies with a narrow window for treatment. We bring bloodwork, cognitive testing, imaging, and specialist review together, coordinated by a clinician who knows how to navigate the process. We’re working to solve one of the biggest bottlenecks in Alzheimer’s care, today. The same store works for both: transparent pricing, clear next steps, and a clinician who helps you get it done. That’s the promise of what we’re building @GeneralMedicine: it’s simple to get the healthcare you need, no matter how complicated it might be We’re excited to work with Lilly to bring both experiences to more people.
19
13
7
140
19,560
LIVE NOW: Less than a year ago, we announced @EliLillyandCo’s decision to invest $3.5 billion in PA, right here in the Lehigh Valley. This project is moving full speed ahead. Join CEO @DaveARicks and me as we break ground on this project. WATCH: nitter.cf/i/broadcasts/2mdrBOebe…
16
8
2
44
7,082
Dave A Ricks retweeted
Presented at #ACR26: The WOMAC pain score and body weight decreased significantly more with retatrutide than with placebo in patients with painful knee osteoarthritis and obesity. Full results of the phase 3 TRIUMPH-4 and TRIUMPH-1-OA trials: nej.md/4A4V4OK @ACRheum
6
26
3
73
15,656
In a head-to-head Phase 3 study in adults with type 2 diabetes, our investigational triple agonist delivered greater reductions in A1C and more than double the weight loss compared to an injectable GLP-1 at 80 weeks. Read more: go.lilly.com/ihqbej
14
13
12
64
9,815
Dave A Ricks retweeted
Presented at #SleepEurope2026: In two phase 3 trials involving participants with OSA and obesity or overweight with or without type 2 diabetes, treatment with retatrutide was found to result in greater decreases in the apnea–hypopnea index than placebo. Full results of the TRIUMPH-1-OSA and TRIUMPH-2-OSA trials: nej.md/4BmAHOI @ESRS_Sleep
14
57
8
177
28,081
Dave A Ricks retweeted
If someone miraculously invented a drug that: - successfully reversed obesity and most of its associated diseases - improved longevity - decreased the long term health costs ….and it was NOT covered by health insurance, …. - then what would be the use of health insurance?
14
11
2
97
5,668
Dave A Ricks retweeted
But AZ and REGN are not R&D underachievers. (With REGN this is largely lack of a new catalyst and worries about the Eylea franchise, I assume.) And there is certainly a lot of market cap gained and destroyed on bubbles, with the genomics bubble of the early 2000s, which inflated big pharma stocks, as a great example. (Actual value created was minimal.)
1
1
1
7
8,836
Dave A Ricks retweeted
If you’re selling longevity, show me the evidence behind the treatment. I like seeing major hospitals get into this field. There’s exciting science here, and they have an opportunity to help establish what actually works. But a compelling theory about aging is only the starting point. Has the treatment been studied in people? Did it improve their health? How meaningful was the benefit, and what were the risks? We don’t need every answer before we explore something new. We do need to be clear about the difference between a promising idea and a proven benefit. Anyone offering a longevity treatment should explain what the data actually show and what remains unproven. People deserve to know.
4
3
1
26
3,874
The heart deserves as much attention as blood sugar in type 2 diabetes. In our largest, longest study of an oral GLP-1, presented at #EASD2026, the trial met its cardiovascular safety endpoint vs. insulin glargine. Read more: go.lilly.com/cmojxu
2
5
23
4,407
Presented at #EASD2026, our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results in adults with obesity and type 2 diabetes: substantial weight loss and A1C reduction. Read more: go.lilly.com/j8vyoc
6
9
2
40
7,433
Dave A Ricks retweeted
Wouldn’t there be a high incentive in stealthily providing additional weight loss promoters such as better lifestyle advice to the single arm? Also, AE comparison much more difficult with single arm.
1
700
Dave A Ricks retweeted
In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz
26
262
112
1,088
417,879
In Milan, Italy, we're opening House of Lilly during #EASD2026. It brings art and science together to share our history, the inspiration behind our innovation and the science behind what comes next as we work to change the course of cardiometabolic health. #WeAreLilly
3
7
5
34
9,231
Dave A Ricks retweeted
One of the most impressive acts of sportsmanship we have seen in a long time. The world needs more of this….
A classy move from Scottie Scheffler. After a fell yelled in Nico's swing, Scottie conceded a 32-footer to tie the hole.
34
30
4
819
633,961